Bleric Alcalá

Bleric Alcalá

Auto-generated profile, based on publicly available information

Bleric Alcalá

Market Access, Merck S.L.U., Madrid, Spain, an affiliate of Merck KGaA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
JMJorge Mestre-Ferrandiz
Jorge Mestre-Ferrandiz
NZNéboa Zozaya
Néboa Zozaya
BABleric Alcalá
Bleric Alcalá
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega

29 May 2018 in BioDrugs
Verified
Journal Article
Open access
PDF file
NZNéboa Zozaya
Néboa Zozaya
LMLucía Martínez-Galdeano
Lucía Martínez-Galdeano
BABleric Alcalá
Bleric Alcalá
JAJose Carlos Armario-Hita
Jose Carlos Armario-Hita
CCConcepción Carmona
Concepción Carmona
ÁHÁlvaro Hidalgo-Vega
Álvaro Hidalgo-Vega
Multi-criteria decision analysis (MCDA) is a tool that systematically considers multiple factors relevant to health decision-making. The aim of this study was to use an MCDA to assess the value of dupilumab for severe atopic dermatitis compared with secukinumab for moderate to severe plaque psoriasis in Spain.

3 April 2020 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
NZNéboa Zozaya
Néboa Zozaya
BRB. Alcalá Revilla
B. Alcalá Revilla
PMP. Arrazola Martínez
P. Arrazola Martínez
JBJ. R. Chávarri Bravo
J. R. Chávarri Bravo
IEI. Cuesta Esteve
I. Cuesta Esteve
AHA. Hidalgo-Vega
A. Hidalgo-Vega
Objective: To advance the development of an ideal and sustainable framework agreement for the public procurement of vaccines in Spain, and to agree on the desirable award criteria and their relative weight. Methods: A multidisciplinary committee of seven health-care professionals and managers developed a partial multi-criteria decision analysis to determine the award criteria that should be considered and their specific weights for the public procurement of routine vaccines and seasonal influenza vaccines, considering their legal viability. A re-test of the results was carried out. The current situation was analyzed through 118 tender specifications and compared to the ideal framework. Results: Price is the prevailing award criterion for the public procurement of both routine (weighting of 60% versus 40% for all other criteria) and influenza (36% versus 64%) vaccines. Ideally, 22 criteria should be considered for routine vaccines, grouped and weighted into five domains: efficacy (weighting of 29%), economic aspects (27%), vaccine characteristics (22%), presentation form and packaging (13%), and others (9%). Per criteria set, price was the most important criterion (22%), followed by effectiveness (9%), and composition/formulation (7%). Regarding influenza vaccines, 20 criteria were selected, grouped, and weighted: efficacy (29%), economic aspects (25%), vaccine characteristics (20%), presentation form and packaging (16%), and others (11%). Per criteria set, price was also the most relevant criterion (19%), followed by composition/formulation (8%), and effectiveness (8%). Conclusions: Contrary to the current approach, technical award criteria should prevail over economic criteria in an ideal and sustainable framework agreement for the public procurement of vaccines.

24 June 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
COCelia Oreja-Guevara
Celia Oreja-Guevara
LLLamberto Landete
Lamberto Landete
MSMiguel Ángel Rodriguez Sagrado
Miguel Ángel Rodriguez Sagrado
IMIsabel Moya
Isabel Moya
BRBleric Alcala Revilla
Bleric Alcala Revilla
LBLluís Brieva
Lluís Brieva
With the expanding range of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS), clinicians face increasing complexity in defining optimal treatment sequences and timing of therapy switches. In this study, we adapted an earlier computer-assisted model to optimize therapeutic decisions and identify preferred treatment pathways, based on expert opinion and observations from clinical practice in Spain. The original model was updated to integrate magnetic resonance imaging (MRI) activity data and define reaching an Expanded Disability Status Scale (EDSS) score of 3 - indicating moderate disability without ambulation impairment - as a criterion for switching treatment. Matrices were designed to model options when switching DMTs, triggered by either a lack of effectiveness or safety concerns. Change in DMT was based on a set of composite criteria (encompassing contributions from relapses, disability worsening, MRI activity, costs, and quality of life) according to the disease activity level. A maximum of three DMTs could be administered within the 8-year time horizon evaluated. The revised model identified high efficacy treatment, in particular cladribine tablets as the preferred initial DMT for patients with RRMS with mild or moderate disease activity. Of these patients with mild and moderate disease activity, most were switched to ofatumumab (79.4%) and ocrelizumab (75.9%), respectively, when disease progression occurred. Patients with high disease activity mostly received natalizumab if they were John Cunningham virus (JCV)-negative, or ocrelizumab if they were JCV-positive. The model is informed by a Spain-based healthcare expert panel and has been evaluated using a simulated cohort of 10,000 patients with RRMS. This computational model helps to inform clinicians towards making optimal treatment decisions for RRMS, and identified high-efficacy DMTs as the preferred model-based option for all levels of disease activity, supporting early and effective control of disease activity in real-world clinical practice.